aTyr Pharma is a biotherapeutics company engaged in the discovery and clinical development of innovative new therapeutic candidates for patients suffering from disease using our knowledge of the extracellular functionality of aminoacyl tRNA synthetases (aaRS).
Our founders, Paul Schimmel, Ph.D. and Xiang-Lei Yang, Ph.D., leading aminoacyl tRNA synthetase researchers at The Scripps Research Institute in San Diego, California, discovered the potential extracellular functionality of aaRS, along with our scientists in San Diego and Hong Kong.
By leveraging our vast patent estate of this newly discovered biology, we aim to build a proprietary pipeline of novel product candidates autonomously and with collaborators.
Our mission is to elucidate the therapeutic potential of these newly discovered proteins.
Click here to learn more about extracellular tRNA synthetase Biology.